Preliminary pre-clinical data for a candidate drug in hearing loss


Sensorion, a French biotech company specializing in the treatment of inner ear diseases, recently announced preclinical results for SENS-401, its candidate drug for the treatment of acute sensorineural hearing loss.

SENS-401 was tested in a proven noise-induced hearing loss model. The in vivo proof-of-concept study involved animals exposed to 120 dB of noise for two hours. The tested animals were then randomly treated over 14 consecutive days with either a placebo or increasing doses of SENS-401 administered orally.

The noise trauma triggered an injury process that affected the inner ear and led to acute hearing loss of more than 60 dB on the first day of the study. After the 14 days of treatment, the residual hearing loss was still about 52 to 59 dB in the placebo group, but just 33 to 49 dB in the SENS-401 treated group.

Chief Medical Officer at Sensorion, Pierre Attali commented that “We are delighted to have had the opportunity to present these encouraging pre-clinical data to the scientific community, which is actively seeking innovative solutions for treating acute sensorineural hearing loss. On the basis of these positive results, we intend to continue the clinical development of SENS-401 in this particularly debilitating pathology for which there is currently no effective treatment.”

The results were presented at the annual general meeting of the Society for Neuroscience (SfN), Neuroscience 2016, held in San Diego, California, on November 16, 2016.

Source: Business Wire